A prospective phase II clinical trial investigated the impact of ERCC1 and ribonucleotide reductase M1 subunit (RRM1), another biomarker that has been associated with treatment response in NSCLC, expression testing on patient outcomes in 55 patients with advanced NSCLC (stage IIIb or stage IV). This evidence concerns the gene RRM1 and non-small cell lung carcinoma.